TY - JOUR
T1 - Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant
T2 - A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
AU - Smith, Jaclyn A.
AU - Birring, Surinder S.
AU - Dicpinigaitis, Peter V.
AU - McGarvey, Lorcan P.
AU - Morice, Alyn H.
AU - Pavord, Ian D.
AU - Satia, Imran
AU - Green, Stuart
AU - Iskold, Beata
AU - La Rosa, Carmen
AU - Li, Qing
AU - Martin Nguyen, Allison
AU - Schelfhout, Jonathan
AU - Muccino, David
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/8
Y1 - 2022/8
N2 - Introduction: In phase 3 trials (COUGH-1/COUGH-2), gefapixant 45 mg twice daily significantly reduced 24-h cough frequency vs placebo in refractory or unexplained chronic cough (RCC or UCC). Methods: Here, the efficacy of gefapixant 45 mg vs placebo was evaluated across COUGH-1/COUGH-2 in predefined subgroups based on sex, region, age, cough duration, cough severity, cough frequency, and diagnosis (RCC, UCC). Awake cough frequency reductions at Week 12 and LCQ response rates (i.e., ≥ 1.3-point improvement) at Week 24 were assessed. Results: Among 1360 participants analyzed, gefapixant 45 mg resulted in consistent awake cough frequency reductions overall and across predefined subgroups at Week 12. Gefapixant also resulted in improved LCQ scores across subgroups at Week 24; ≥ 70% of participants in each subgroup treated with gefapixant 45 mg had an LCQ response. Conclusion: These data suggest gefapixant 45 mg provides consistent objective and subjective efficacy across subgroups of individuals with RCC or UCC.
AB - Introduction: In phase 3 trials (COUGH-1/COUGH-2), gefapixant 45 mg twice daily significantly reduced 24-h cough frequency vs placebo in refractory or unexplained chronic cough (RCC or UCC). Methods: Here, the efficacy of gefapixant 45 mg vs placebo was evaluated across COUGH-1/COUGH-2 in predefined subgroups based on sex, region, age, cough duration, cough severity, cough frequency, and diagnosis (RCC, UCC). Awake cough frequency reductions at Week 12 and LCQ response rates (i.e., ≥ 1.3-point improvement) at Week 24 were assessed. Results: Among 1360 participants analyzed, gefapixant 45 mg resulted in consistent awake cough frequency reductions overall and across predefined subgroups at Week 12. Gefapixant also resulted in improved LCQ scores across subgroups at Week 24; ≥ 70% of participants in each subgroup treated with gefapixant 45 mg had an LCQ response. Conclusion: These data suggest gefapixant 45 mg provides consistent objective and subjective efficacy across subgroups of individuals with RCC or UCC.
KW - Antitussives
KW - Cough frequency
KW - P2X3-receptor antagonist
KW - Patient-reported outcomes
KW - Refractory chronic cough
KW - Unexplained chronic cough
UR - http://www.scopus.com/inward/record.url?scp=85135547934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135547934&partnerID=8YFLogxK
U2 - 10.1007/s00408-022-00553-y
DO - 10.1007/s00408-022-00553-y
M3 - Article
C2 - 35895098
AN - SCOPUS:85135547934
SN - 0341-2040
VL - 200
SP - 423
EP - 429
JO - Lung
JF - Lung
IS - 4
ER -